Ok, so what should be different about the company in 5 years from now? Here are a few things that come to mind, but I am probably still missing some things.
1. RECESS 2 study complete and likely successful because of the experience from RECESS 1, IIT in the EU and Cytosorb Registry data collected prior to trial start.
2. Germany Endocarditis study complete.
3. Hemodefend study complete and hopefully a partner with licensing agreement in place and the partner has commercialized the product.
4. US sepsis trial in full swing and likely close to fully populated.
5. International Cytosorb Registry fully enrolled with 3000 cases for treatment of many different issues and data available to clinicians.
6. Advancement of the Potassium filter in the pipeline.
7. Advancement of potassium filter.
8. 5 years of partners ramping up marketing in sales. Remember
Dr. Chan has stated that Germany is about 3 years ahead of the other countries as far as marketing and sales, so where should these other 50+ countries be in 5 years.
9. Tender orders?
10. Sales in Canada and other countries that use the FDA clearance for their standard for approval.
11. 50+ investigator initiated trial, most of which should be completed within 5 years.
12. Likely start, if not completion of an addition US study for Bilirubin removal.
13. Likely start, if not completion of an additional US study for Myoglobin removal.
900M Market cap in 5 years? Yes, I would not be happy with that. It is less than a triple from here. 900M in annual sales, yes, that would work for me. Yet it doesn't sound like they believe production capacity needs to be near that level in this timeframe, so perhaps your expectations are more realistic. If that is where we are in 5 years, which I doubt, I am not taking it to the bank, I am holding out. Of course I will pick up some new trading shares along the way for my side bets and may dabble with the options market a bit.
